Drug Trial Radar · NCT04445519
Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Last checked: Nov 19, 2026Latest source record: Jun 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
691
Actual
Start
Jun 1, 2020
Primary completion
Sep 16, 2022
Study completion Sep 16, 2022
Sponsor
- Lead sponsor
- Nicox Ophthalmics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 84 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. In the adaptive dose selection phase of the trial, subjects will be randomized in a 1:1:1 ratio to one of two doses of NCX 470 (0.065% or 0.1%) or to latanoprost 0.005%. Following the selection of one dose of NCX 470, subjects will be randomized in a 1:1 ratio to the chosen dose of NCX 470 or to latanoprost 0.005%.
Conditions
- Open Angle Glaucoma
- Ocular Hypertension
Interventions
NCX 470 0.065% (initial phase of trial)Drug
NCX 470 Ophthalmic Solution, 0.065% (initial phase of trial)
Latanoprost 0.005% (initial phase of trial)Drug
Latanoprost Ophthalmic Solution, 0.005%
NCX 470 0.1% (initial phase of trial)Drug
NCX 470 Ophthalmic Solution, 0.1%
NCX 470 0.1% (remainder of trial)Drug
NCX 470 Ophthalmic Solution, 0.1%
Latanoprost 0.005% (remainder of trial)Drug
Latanoprost Ophthalmic Solution, 0.005%
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean IOP Reduction From Time-Matched Baseline at the 8AM and 4PM Time-Points at Week 2, Week 6, and Month 3Time frame: Baseline, Week 2, Week 6, and Month 3
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Eye Research Foundation
Newport Beach, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.